Epigenomics of High Risk Pediatric T Cell Leukemia |
New York University School of Medicine / Iannis Aifantis, PhD |
Reach Grants |
2013 |
New York |
Development of a Pharmacodynamic Marker of EWS-FLI1 Activity to Aid in the Clinical Translation of Targeted Therapies for Ewing sarcoma |
Van Andel Research Institute / Patrick Grohar, MD, PhD |
Reach Grants |
2013 |
Michigan |
Adoptive Immunotherapy of Tr1 Cells to Improve Outcome of Allo-HSCT Treatment for Pediatric AML |
Stanford University / Maria-Grazia Roncarolo, MD & Rosa Bachetta, MD |
Reach Grants |
2015 |
California |
Targeting PI3Kdelta in Childhood Acute Lymphoblastic Leukemia |
Children’s Hospital Los Angeles / Yong-mi Kim, MD & Nora Heisterkamp, PhD |
Reach Grants |
2015 |
California |
Optimizing TCRαβ+/CD19+-depleted haploidentical HSCT for ALL using donor-derived genome-edited CAR T cells |
Stanford University School of Medicine / Alice Bertaina, MD/PhD |
Reach Grants |
2019 |
California |
Stapled Peptide PROTAC: A 3-in-1 Treatment for Pediatric Solid Tumors |
Dana-Farber Cancer Institute / Loren Walensky, MD/PhD |
Reach Grants |
2021 |
Massachusetts |
Multivalent Nanomedicine to Treat High-Risk Pediatric Solid Tumors |
Children’s Hospital of Philadelphia / Garrett Brodeur, MD |
Reach Grants |
2019 |
Pennsylvania |
Circumventing Pediatric Solid Tumor Microenvironment Resistance by Combinatorial CAR NK and Immunomodulating Therapy |
New York Medical College / Mitchell Cairo, MD |
Reach Grants |
2023 |
New York |
Feasibility Study of Dual Inhibition of MDM2 and Tubulin in Treatment of AML |
Emory University / Muxiang Zhou, MD |
Reach Grants |
2023 |
Georgia |
Novel Therapy for Pediatric Leukemia Patients with NUP98 Translocations |
The Regents of the University of Michigan / Jolanta Grembecka, PhD |
Reach Grants |
2022 |
Michigan |